高级检索
当前位置: 首页 > 详情页

Operative intervention for recurrence of adrenocortical carcinoma: A single-center experience.

文献详情

资源类型:
Pubmed体系:
机构: [1]Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
出处:
ISSN:

摘要:
Adrenocortical carcinoma is a rare endocrine malignancy with a high recurrence rate. The aim of this study was to evaluate the role of surgery for patients with local or distant recurrent adrenocortical carcinoma and to attempt to identify prognostic features related to survival benefit in patients undergoing resection of recurrence. The data of 47 patients with recurrent adrenocortical carcinoma in West China Hospital, Sichuan, China, between 2009 and 2019 were retrospectively collected. These patients were divided into 2 groups according to whether resection of recurrence was performed. The correlation between overall survival after recurrence and reoperation was evaluated. Kaplan-Meier and univariate/multivariate Cox regression methods were used to identify any prognostic factors. Included in our study were 21 patients who underwent reoperation and 26 patients who underwent nonoperative treatments were. The operation group had a better median overall survival after recurrence than the nonoperation group (19 months versus 6.5 months; P = .007). In the operated group, disease-free interval >12 months (P = .002), complete resection of recurrent adrenocortical carcinoma (P = .041), and R0 resection of the primary tumor (P = .005) were associated with prolonged survival after recurrence. Reoperation plays an important role in the management of selected patients with recurrent adrenocortical carcinoma. Disease-free interval, preoperative evaluation for complete resection, and R0 resection of the primary tumor are important prognostic characteristics for the resection of recurrent adrenocortical carcinoma. The overall survival after recurrence was significantly improved for patients who had a disease-free interval >12 months, and initial R0 resection or complete resection of recurrent adrenocortical carcinoma is feasible. Copyright © 2020 Elsevier Inc. All rights reserved.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 2 区 医学
小类 | 2 区 外科
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 外科
第一作者:
第一作者机构: [1]Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者:
通讯作者:
通讯机构: [1]Institute of Urology, Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]Sichuan University West China Hospital, Department of Urology, Sichuan University, Chengdu 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号